Clinical trials of GLP-1 and related incretin-based medications have shown meaningful average weight loss over longer treatment periods, depending on the medication, dose, study population, adherence, and duration of therapy
A 2024 review documented studies across gastric, intestinal, musculoskeletal, vascular, neural, and dermal tissue (PMID 38980576)
Step 4, Check the date
To help treat and manage heartburn: Take over-the-counter antacids like Tums or Pepcid, as recommended by your provider
For patient-friendly dosing details and safety caveats, see the Mayo Clinic drug page for semaglutide , then confirm any changes with your prescriber, especially if you manage diabetes
In patients with ASCVD and BMI 30 kg/m, evolocumab was associated with a greater reduction in major adverse cardiovascular events, with a more favorable NNT compared with normal-weight individuals